Trends in the approval of cancer therapies by the FDA in the twenty-first century
Emma ScottOffice of Oncologic Diseases, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, USA. [email protected]Andrea BainesOffice of Oncologic Diseases, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, USAYutao GongOffice of Oncologic Diseases, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, USARodney MooreOffice of Oncologic Diseases, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, USAGülsüm Emel PamukOffice of Oncologic Diseases, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, USAHaleh SaberOffice of Oncologic Diseases, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, USAAshim SubedeeNational Cancer Institute, Rockville, MD, USAMatthew D. ThompsonOffice of Oncologic Diseases, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, USAWenming XiaoOffice of Oncologic Diseases, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, USARichard PazdurOncology Center of Excellence, U.S. Food and Drug Administration, Silver Spring, MD, USAV. Ashutosh RaoOffice of Biotechnology Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, USAJulie A. SchneiderOncology Center of Excellence, U.S. Food and Drug Administration, Silver Spring, MD, USAJulia A. BeaverOffice of Oncologic Diseases, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, USA
2023en
ABI
Abstract
No abstract available.
Identifiers
Citations and references
Cited by 20 references